References
- Bach AW, Lan NC, Johnson DL, et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 1988;85:4934–8
- Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 2008;60:1527–33
- Murphy DL. Substrate-selective monoamine oxidases-inhibitor, tissue, species and functional differences. Biochem Pharmacol 1978;27:1889–93
- Strolin Benedetti M, Dostert P. Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 1989;38:555–61
- Trillo L, Das D, Hsieh W, et al. Ascending monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care. Neurosci Biobehav Rev 2013;37:1363–79
- Davie CA. A review of Parkinson’s disease. Br Med Bull 2008;86:109–27
- Willner P, Scheel-Krüger J, Belzung C. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev 2013;37:2331–71
- Carradori S, D’Ascenzio M, Chimenti P, et al. Selective MAO-B inhibitors: a lesson from natural products. Mol Divers 2014;18:219–43
- Secci D, Carradori S, Bolasco A, et al. Discovery and optimization of pyrazoline derivatives as promising monoamine oxidase inhibitors. Curr Top Med Chem 2012;12:2240–57
- Carradori S, Secci D, Bolasco A, et al. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2012;22:759–801
- Secci D, Bolasco A, Chimenti P, Carradori S. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents. Curr Med Chem 2011;18:5114–44
- Bolasco A, Carradori S, Fioravanti R. Focusing on new monoamine oxidase inhibitors. Expert Opin Ther Pat 2010;20:909–39
- Bolasco A, Fioravanti R, Carradori S. Recent development of monoamine oxidase inhibitors. Expert Opin Ther Pat 2005;15:1763–82
- Ramsay RR. Inhibitor design for monoamine oxidases. Curr Pharm Des 2013;19:2529–39
- Carreiras MC, Mendes E, Perry MJ, et al. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Top Med Chem 2013;13:1745–70
- Bolognesi ML, Rosini M, Andrisano V, et al. MTDL design strategy in the contextof Alzheimeir’s disease: from lipocrine to memoquin and beyond. Curr Pharm Des 2009;15:601–13
- Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347–72
- Bautista-Aguilera OM, Esteban G, Bolea I, et al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donezepil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease. Eur J Med Chem 2014;75:82–95
- Di Giovanni G, García I, Colangeli R, et al. N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): a potential cognitive enhancer with MAO inhibitor properties. CNS Neurosci Ther 2014;20:633–40
- Cappelli A, Gallelli A, Manini M, et al. Further studies on the interaction of the 5-HT3 receptor with arylpiperazine ligands. Development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties. J Med Chem 2005;48:3564–75
- Colovic MB, Krstic DZ, Lazarevic-Pasti TD, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013;11:315–35
- Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis 2012;2012:728983
- Chimenti P, Petzer A, Carradori S, et al. Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors. Eur J Med Chem 2013;66:221–7
- Secci D, Bolasco A, Carradori S, et al. Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines. Eur J Med Chem 2012;58:405–17
- Secci D, Carradori S, Bolasco A, et al. Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives. Eur J Med Chem 2011;46:4846–52
- Chimenti F, Carradori S, Secci D, et al. Synthesis and biological evaluation of novel conjugated coumarin-thiazole systems. J Heterocyclic Chem 2009;46:575–8
- Raza R, Saeed A, Arif M, et al. Synthesis and biological evaluation of 3-thiazolocoumarinyl Schiff-base derivatives as cholinesterase inhibitors. Chem Biol Drug Des 2012;80:605–15
- Chimenti F, Secci D, Bolasco A, et al. Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones. Med Chem Commun 2010;1:61–72
- Carradori S, D’Ascenzio M, De Monte C, et al. Synthesis and selective human monoamine oxidase B inhibition of heterocyclic hybrids based on hydrazine and thiazole scaffolds. Arch Pharm 2013;346:17–22
- D’Ascenzio M, Carradori S, Secci D, et al. Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors. Bioorg Med Chem 2014;22:2887–95
- Chimenti F, Secci D, Bolasco A, et al. Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem 2010;18:5063–70
- Chimenti F, Secci D, Bolasco A, et al. Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of potent and selective human monoamine oxidase inhibitors. Bioorg Med Chem 2010;18:5715–23
- Yáñez M, Fraiz N, Cano E, Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun 2006;344:688–95
- Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95
- Friggeri L, De Vita D, Pandolfi F, et al. Design, synthesis and evaluation of 3,4-dihydroxybenzoic acid derivatives as antioxidants, bio-metal chelating agents and acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem 2014. doi:10.3109/14756366.2013.866657
- Glide, version 6.2. New York (NY): Schrödinger, LLC; 2014
- Prime version 3.4. New York (NY): Schrödinger, LLC; 2014
- De Colibus L, Li M, Binda C, et al. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 2005;36:12684–9
- Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235–42
- Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50:5848–52
- Desmond Molecular Dynamics System, version 3.7, D. E. Shaw Research, New York, NY, 2014. Maestro-Desmond Interoperability Tools, version 3.7. New York (NY): Schrödinger; 2014
- Kryger G, Silman L, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999;7:297–307
- MacroModel, version 10.3, Schrödinger, LLC, New York, NY, 2014
- Chimenti F, Bizzarri B, Bolasco A, et al. Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents. Eur J Med Chem 2011;46:378–82
- Secci D, Bizzarri B, Bolasco A, et al. Synthesis, anti-Candida activity, and cytotoxicity of new (4-(4-iodophenyl)thiazol-2-yl)hydrazine derivatives. Eur J Med Chem 2012;53:246–53
- Chimenti F, Bizzarri B, Bolasco A, et al. Synthesis and anti-Helicobacter pylori activity of 4-(coumarin-3-yl)thiazol-2-ylhydrazone derivatives. J Heterocyclic Chem 2010;47:1269–74
- Hassan AA, Ibrahim YR, El-Sheref EM, et al. Synthesis and antibacterial activity of 4-aryl-2-(1-substituted ethylidene)thiazoles. Arch Pharm 2013;346:562–70
- Carradori S, Rotili D, De Monte C, et al. Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: enzyme and cellular studies. Eur J Med Chem 2014;8:569–78
- Son SY, Ma J, Kondou Y, et al. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008;105:5739–44
- Maestro, version 9.7. New York (NY): Schrödinger, LLC; 2014
- LigPrep, version 2.9. New York (NY): Schrödinger, LLC; 2014
- The PyMOL Molecular Graphics System, version 1.7.0.0 Schrödinger, LLC